Marla D. Lipsyc-Sharf

Clinical trials

• Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

  Principal investigator · Recruiting · Phase 2

  Jonsson Comprehensive Cancer Center

  2026–2031
• Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

  Site PI · Recruiting

  Natera, Inc.

  2026–2037
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

  Site PI · Recruiting · Phase 3

  Stemline Therapeutics, Inc.

  2024–2032
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  Site PI · Recruiting · Phase 3

  NRG Oncology

  2023–2034